Turn Therapeutics Inc.

Clinical/early-stage biotech — near-insolvent.

Strengths

• Liquidity — current ratio 0.87 (13th)

Risks

• Pre-revenue, deep losses — per metrics
• Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
• Binary clinical & funding risk — per 10-K

Notable findings

• Going concernOur consolidated financial statements therefore express substantial doubt about our ability to continue as a going concern
• Exec changeRecent 8-K item 5.02 8-K ↗
• Weak liquidityCurrent ratio 0.87 (<1)
• Material weakness● We identified a material weakness in our internal control over the accuracy of our financial reporting, and our management concluded that our internal controls over financial reporting were not e
• Notable holderHeld by 2 notable fund(s): VANGUARD GROUP INC, CITADEL ADVISORS LLC (as of 2025-12-31)